Article

Kala submits IND for postop cataract surgery agent

Kala Pharmaceuticals Inc. has submitted an Investigational New Drug (IND) application to the FDA to initiate a phase III clinical program with its mucus-penetrating particle (MPP) technology-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP).

 

Waltham, MA-Kala Pharmaceuticals Inc. has submitted an Investigational New Drug (IND) application to the FDA to initiate a phase III clinical program with its mucus-penetrating particle (MPP) technology-formulated loteprednol etabonate ophthalmic nano-suspension product (LE-MPP).

The drug is indicated for postoperative inflammation and pain following cataract surgery.

Kala’s MPP technology platform allows therapeutic agents to pass through the mucus layer of the ocular surface, facilitating penetration into deeper tissues of the eye, including the aqueous humor and retina. It is also designed to potentiate pharmacological effects within target tissues.

The objective of the upcoming clinical trial is the demonstrate anti-inflammatory efficacy similar to that of other steroid-based treatments with less frequent (twice-daily) dosing, while maintaining the safety profile of current loteprednol etabonate products.

According to Kim Brazzell, PhD, Kala’s chief medical officer, in preclinical studies, LE-MPP demonstrated a superior pharmacokinetics profile in target tissues compared to currently marketed loteprednol etabonate products. In head-to-head preclinical studies, LE-MPP delivered significantly greater levels of drug to the aqueous humor-as well as the cornea, conjunctiva, and retina-than either Lotemax Suspension or Lotemax Gel with similar dosing regimens.

“If (the upcoming clinical trial is) successful, this would represent a significant dosing advantage compared to other topical steroids, which are currently indicated for four times a day dosing,” Dr. Brazzell said.

“The global topical corticosteroid market is significant and growing based on the aging population,” said Guillaume Pfefer, Ph.D., president and chief executive officer of Kala. “A topical corticosteroid with superior penetration, pharmacokinetics, and a more favorable dosing regimen would be a welcome alternative to current treatment regimens.”

“It’s exciting to see nanoparticle technology moving to the forefront of the ophthalmology field,” said Terry Kim, MD, professor of ophthalmology at Duke University Eye Center, Durham, NC. “By combining small particle size and state-of-the-art surface engineering techniques, physicians and patients should benefit from a variety of new and improved therapeutic options across ophthalmic disease states.”

Beyond the post-surgical program, Dr. Pfefer said Kala plans to initiate clinical programs with lower doses of LE-MPP in both dry eye disease and blepharitis in 2014.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

 

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.